Press Release, 6 January 2016

Cytos Biotechnology Ltd (“Cytos” or the “Company”), announced today that its shareholders have approved all resolutions at today’s Extraordinary Shareholders’ Meeting with overwhelming majority. These resolutions, among other things, consist of an ordinary capital increase of around 392 million shares which will be used to acquire Kuros Biosurgery Ltd. After the capital increase, a total of around 500 million Cytos shares with a nominal value of CHF 0.01 each will be issued and outstanding.

Schlieren (Zurich), Switzerland, January 6, 2016

The Extraordinary Shareholders’ Meeting of Cytos Biotechnology Ltd took place at the Company’s headquarters in Schlieren (Zurich), Switzerland. It was attended by 92 shareholders. 23’555’497 shares or 21.8% of a total of 108’015’276 shares were represented.

Additional information can be retrieved in our press releases dated December 3, 2015 and December 15, 2015.

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward- looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

For further information, please contact:

Cytos Biotechnology Ltd

Harry Welten, MBA Chief Financial Officer

Tel: +41 44 733 46 46

harry.welten@cytos.com